Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma
NCT02540161
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
43
Enrollment
OTHER
Sponsor class
Conditions
Malignant Glioma
Interventions
DRUG:
Sym004 - 18 mg/kg
DRUG:
Sym004 - 24 mg/kg
Sponsor
Annick Desjardins
Collaborators
[object Object]